nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—JUN—Vinblastine—testicular cancer	0.526	0.656	CbGbCtD
Irbesartan—PTGS1—Ifosfamide—testicular cancer	0.069	0.0859	CbGbCtD
Irbesartan—CYP2C8—Ifosfamide—testicular cancer	0.0398	0.0496	CbGbCtD
Irbesartan—PTGS1—Etoposide—testicular cancer	0.033	0.0411	CbGbCtD
Irbesartan—CYP2C9—Ifosfamide—testicular cancer	0.0278	0.0346	CbGbCtD
Irbesartan—CYP2C8—Etoposide—testicular cancer	0.019	0.0237	CbGbCtD
Irbesartan—CYP3A4—Ifosfamide—testicular cancer	0.0161	0.0201	CbGbCtD
Irbesartan—CYP1A2—Etoposide—testicular cancer	0.0147	0.0183	CbGbCtD
Irbesartan—CYP2C9—Cisplatin—testicular cancer	0.0135	0.0168	CbGbCtD
Irbesartan—CYP2D6—Vinblastine—testicular cancer	0.0135	0.0168	CbGbCtD
Irbesartan—CYP3A4—Vinblastine—testicular cancer	0.00856	0.0107	CbGbCtD
Irbesartan—CYP2D6—Doxorubicin—testicular cancer	0.00827	0.0103	CbGbCtD
Irbesartan—CYP3A4—Etoposide—testicular cancer	0.00771	0.00961	CbGbCtD
Irbesartan—CYP3A4—Doxorubicin—testicular cancer	0.00526	0.00656	CbGbCtD
Irbesartan—EDNRA—seminal vesicle—testicular cancer	0.00156	0.122	CbGeAlD
Irbesartan—JUN—embryo—testicular cancer	0.00151	0.118	CbGeAlD
Irbesartan—JUN—seminal vesicle—testicular cancer	0.00142	0.111	CbGeAlD
Irbesartan—JUN—gonad—testicular cancer	0.00103	0.0802	CbGeAlD
Irbesartan—EDNRA—female gonad—testicular cancer	0.000914	0.0714	CbGeAlD
Irbesartan—JUN—female gonad—testicular cancer	0.000834	0.0652	CbGeAlD
Irbesartan—EDNRA—testis—testicular cancer	0.00081	0.0634	CbGeAlD
Irbesartan—JUN—testis—testicular cancer	0.000739	0.0578	CbGeAlD
Irbesartan—EDNRA—lymph node—testicular cancer	0.000587	0.0459	CbGeAlD
Irbesartan—AGTR1—testis—testicular cancer	0.000557	0.0435	CbGeAlD
Irbesartan—JUN—lymph node—testicular cancer	0.000536	0.0419	CbGeAlD
Irbesartan—PTGS1—seminal vesicle—testicular cancer	0.00047	0.0367	CbGeAlD
Irbesartan—AGTR1—lymph node—testicular cancer	0.000404	0.0316	CbGeAlD
Irbesartan—CYP2C8—testis—testicular cancer	0.000302	0.0236	CbGeAlD
Irbesartan—PTGS1—female gonad—testicular cancer	0.000276	0.0216	CbGeAlD
Irbesartan—PTGS1—testis—testicular cancer	0.000245	0.0191	CbGeAlD
Irbesartan—CYP2D6—female gonad—testicular cancer	0.000227	0.0177	CbGeAlD
Irbesartan—CYP2D6—testis—testicular cancer	0.000201	0.0157	CbGeAlD
Irbesartan—PTGS1—lymph node—testicular cancer	0.000177	0.0139	CbGeAlD
Irbesartan—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.000159	0.0749	CbGpPWpGaD
Irbesartan—Urethral disorder—Methotrexate—testicular cancer	0.000144	0.00079	CcSEcCtD
Irbesartan—Feeling abnormal—Etoposide—testicular cancer	0.000144	0.000788	CcSEcCtD
Irbesartan—Hyperglycaemia—Doxorubicin—testicular cancer	0.000144	0.000786	CcSEcCtD
Irbesartan—Nausea—Dactinomycin—testicular cancer	0.000143	0.000784	CcSEcCtD
Irbesartan—Agranulocytosis—Epirubicin—testicular cancer	0.000143	0.000784	CcSEcCtD
Irbesartan—Pneumonia—Doxorubicin—testicular cancer	0.000143	0.000782	CcSEcCtD
Irbesartan—Gastrointestinal pain—Etoposide—testicular cancer	0.000143	0.000781	CcSEcCtD
Irbesartan—Visual impairment—Methotrexate—testicular cancer	0.000142	0.000776	CcSEcCtD
Irbesartan—Vomiting—Ifosfamide—testicular cancer	0.000141	0.000769	CcSEcCtD
Irbesartan—Hypersensitivity—Cisplatin—testicular cancer	0.00014	0.000769	CcSEcCtD
Irbesartan—Bradycardia—Epirubicin—testicular cancer	0.00014	0.000768	CcSEcCtD
Irbesartan—Renal failure—Doxorubicin—testicular cancer	0.00014	0.000764	CcSEcCtD
Irbesartan—Rash—Ifosfamide—testicular cancer	0.000139	0.000763	CcSEcCtD
Irbesartan—Dermatitis—Ifosfamide—testicular cancer	0.000139	0.000762	CcSEcCtD
Irbesartan—Urticaria—Etoposide—testicular cancer	0.000139	0.000759	CcSEcCtD
Irbesartan—Jaundice—Doxorubicin—testicular cancer	0.000138	0.000758	CcSEcCtD
Irbesartan—Rhinitis—Epirubicin—testicular cancer	0.000138	0.000756	CcSEcCtD
Irbesartan—Abdominal pain—Etoposide—testicular cancer	0.000138	0.000755	CcSEcCtD
Irbesartan—Body temperature increased—Etoposide—testicular cancer	0.000138	0.000755	CcSEcCtD
Irbesartan—Urinary tract infection—Doxorubicin—testicular cancer	0.000138	0.000755	CcSEcCtD
Irbesartan—Conjunctivitis—Doxorubicin—testicular cancer	0.000138	0.000755	CcSEcCtD
Irbesartan—Hepatitis—Epirubicin—testicular cancer	0.000138	0.000754	CcSEcCtD
Irbesartan—Tinnitus—Methotrexate—testicular cancer	0.000137	0.000751	CcSEcCtD
Irbesartan—Hypoaesthesia—Epirubicin—testicular cancer	0.000137	0.00075	CcSEcCtD
Irbesartan—Asthenia—Cisplatin—testicular cancer	0.000137	0.000748	CcSEcCtD
Irbesartan—Pharyngitis—Epirubicin—testicular cancer	0.000137	0.000748	CcSEcCtD
Irbesartan—Cardiac disorder—Methotrexate—testicular cancer	0.000137	0.000748	CcSEcCtD
Irbesartan—Urinary tract disorder—Epirubicin—testicular cancer	0.000136	0.000745	CcSEcCtD
Irbesartan—Oedema peripheral—Epirubicin—testicular cancer	0.000136	0.000743	CcSEcCtD
Irbesartan—Connective tissue disorder—Epirubicin—testicular cancer	0.000135	0.000741	CcSEcCtD
Irbesartan—Urethral disorder—Epirubicin—testicular cancer	0.000135	0.000739	CcSEcCtD
Irbesartan—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000134	0.000735	CcSEcCtD
Irbesartan—Epistaxis—Doxorubicin—testicular cancer	0.000134	0.000733	CcSEcCtD
Irbesartan—Angiopathy—Methotrexate—testicular cancer	0.000134	0.000731	CcSEcCtD
Irbesartan—Immune system disorder—Methotrexate—testicular cancer	0.000133	0.000728	CcSEcCtD
Irbesartan—Visual impairment—Epirubicin—testicular cancer	0.000133	0.000727	CcSEcCtD
Irbesartan—Mediastinal disorder—Methotrexate—testicular cancer	0.000133	0.000726	CcSEcCtD
Irbesartan—Agranulocytosis—Doxorubicin—testicular cancer	0.000133	0.000725	CcSEcCtD
Irbesartan—Chills—Methotrexate—testicular cancer	0.000132	0.000723	CcSEcCtD
Irbesartan—Nausea—Ifosfamide—testicular cancer	0.000131	0.000719	CcSEcCtD
Irbesartan—Diarrhoea—Cisplatin—testicular cancer	0.00013	0.000714	CcSEcCtD
Irbesartan—Bradycardia—Doxorubicin—testicular cancer	0.00013	0.00071	CcSEcCtD
Irbesartan—Hypersensitivity—Etoposide—testicular cancer	0.000129	0.000704	CcSEcCtD
Irbesartan—Tinnitus—Epirubicin—testicular cancer	0.000128	0.000703	CcSEcCtD
Irbesartan—Malnutrition—Methotrexate—testicular cancer	0.000128	0.000701	CcSEcCtD
Irbesartan—Erythema—Methotrexate—testicular cancer	0.000128	0.000701	CcSEcCtD
Irbesartan—Flushing—Epirubicin—testicular cancer	0.000128	0.0007	CcSEcCtD
Irbesartan—Cardiac disorder—Epirubicin—testicular cancer	0.000128	0.0007	CcSEcCtD
Irbesartan—Rhinitis—Doxorubicin—testicular cancer	0.000128	0.000699	CcSEcCtD
Irbesartan—Hepatitis—Doxorubicin—testicular cancer	0.000127	0.000698	CcSEcCtD
Irbesartan—Hypoaesthesia—Doxorubicin—testicular cancer	0.000127	0.000694	CcSEcCtD
Irbesartan—Pharyngitis—Doxorubicin—testicular cancer	0.000127	0.000692	CcSEcCtD
Irbesartan—Urinary tract disorder—Doxorubicin—testicular cancer	0.000126	0.000689	CcSEcCtD
Irbesartan—Oedema peripheral—Doxorubicin—testicular cancer	0.000126	0.000687	CcSEcCtD
Irbesartan—Dysgeusia—Methotrexate—testicular cancer	0.000126	0.000687	CcSEcCtD
Irbesartan—Asthenia—Etoposide—testicular cancer	0.000125	0.000686	CcSEcCtD
Irbesartan—Connective tissue disorder—Doxorubicin—testicular cancer	0.000125	0.000686	CcSEcCtD
Irbesartan—Angiopathy—Epirubicin—testicular cancer	0.000125	0.000684	CcSEcCtD
Irbesartan—Urethral disorder—Doxorubicin—testicular cancer	0.000125	0.000684	CcSEcCtD
Irbesartan—Immune system disorder—Epirubicin—testicular cancer	0.000124	0.000681	CcSEcCtD
Irbesartan—Mediastinal disorder—Epirubicin—testicular cancer	0.000124	0.00068	CcSEcCtD
Irbesartan—Chills—Epirubicin—testicular cancer	0.000124	0.000677	CcSEcCtD
Irbesartan—Pruritus—Etoposide—testicular cancer	0.000124	0.000676	CcSEcCtD
Irbesartan—Arrhythmia—Epirubicin—testicular cancer	0.000123	0.000674	CcSEcCtD
Irbesartan—Visual impairment—Doxorubicin—testicular cancer	0.000123	0.000672	CcSEcCtD
Irbesartan—Vomiting—Cisplatin—testicular cancer	0.000121	0.000663	CcSEcCtD
Irbesartan—Vision blurred—Methotrexate—testicular cancer	0.000121	0.000661	CcSEcCtD
Irbesartan—Rash—Cisplatin—testicular cancer	0.00012	0.000658	CcSEcCtD
Irbesartan—Dermatitis—Cisplatin—testicular cancer	0.00012	0.000657	CcSEcCtD
Irbesartan—Erythema—Epirubicin—testicular cancer	0.00012	0.000656	CcSEcCtD
Irbesartan—Malnutrition—Epirubicin—testicular cancer	0.00012	0.000656	CcSEcCtD
Irbesartan—Diarrhoea—Etoposide—testicular cancer	0.000119	0.000654	CcSEcCtD
Irbesartan—UGT1A3—NRF2 pathway—SLC2A6—testicular cancer	0.000119	0.0561	CbGpPWpGaD
Irbesartan—Ill-defined disorder—Methotrexate—testicular cancer	0.000119	0.000651	CcSEcCtD
Irbesartan—Tinnitus—Doxorubicin—testicular cancer	0.000119	0.00065	CcSEcCtD
Irbesartan—Anaemia—Methotrexate—testicular cancer	0.000118	0.000648	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—testicular cancer	0.000118	0.000647	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—testicular cancer	0.000118	0.000647	CcSEcCtD
Irbesartan—Flatulence—Epirubicin—testicular cancer	0.000118	0.000647	CcSEcCtD
Irbesartan—Tension—Epirubicin—testicular cancer	0.000118	0.000644	CcSEcCtD
Irbesartan—Dysgeusia—Epirubicin—testicular cancer	0.000117	0.000643	CcSEcCtD
Irbesartan—Nervousness—Epirubicin—testicular cancer	0.000117	0.000638	CcSEcCtD
Irbesartan—Angiopathy—Doxorubicin—testicular cancer	0.000116	0.000633	CcSEcCtD
Irbesartan—Malaise—Methotrexate—testicular cancer	0.000116	0.000633	CcSEcCtD
Irbesartan—Dizziness—Etoposide—testicular cancer	0.000115	0.000632	CcSEcCtD
Irbesartan—Muscle spasms—Epirubicin—testicular cancer	0.000115	0.000631	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—testicular cancer	0.000115	0.00063	CcSEcCtD
Irbesartan—Vertigo—Methotrexate—testicular cancer	0.000115	0.00063	CcSEcCtD
Irbesartan—Mediastinal disorder—Doxorubicin—testicular cancer	0.000115	0.000629	CcSEcCtD
Irbesartan—Leukopenia—Methotrexate—testicular cancer	0.000115	0.000628	CcSEcCtD
Irbesartan—Chills—Doxorubicin—testicular cancer	0.000114	0.000626	CcSEcCtD
Irbesartan—Arrhythmia—Doxorubicin—testicular cancer	0.000114	0.000623	CcSEcCtD
Irbesartan—Nausea—Cisplatin—testicular cancer	0.000113	0.00062	CcSEcCtD
Irbesartan—Vision blurred—Epirubicin—testicular cancer	0.000113	0.000619	CcSEcCtD
Irbesartan—Cough—Methotrexate—testicular cancer	0.000112	0.000612	CcSEcCtD
Irbesartan—Ill-defined disorder—Epirubicin—testicular cancer	0.000111	0.000609	CcSEcCtD
Irbesartan—Vomiting—Etoposide—testicular cancer	0.000111	0.000608	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—testicular cancer	0.000111	0.000607	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—testicular cancer	0.000111	0.000607	CcSEcCtD
Irbesartan—Anaemia—Epirubicin—testicular cancer	0.000111	0.000607	CcSEcCtD
Irbesartan—Agitation—Epirubicin—testicular cancer	0.00011	0.000603	CcSEcCtD
Irbesartan—Rash—Etoposide—testicular cancer	0.00011	0.000603	CcSEcCtD
Irbesartan—Dermatitis—Etoposide—testicular cancer	0.00011	0.000602	CcSEcCtD
Irbesartan—EDNRA—Peptide ligand-binding receptors—INSL3—testicular cancer	0.00011	0.0519	CbGpPWpGaD
Irbesartan—Headache—Etoposide—testicular cancer	0.000109	0.000599	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—testicular cancer	0.000109	0.000598	CcSEcCtD
Irbesartan—Arthralgia—Methotrexate—testicular cancer	0.000109	0.000597	CcSEcCtD
Irbesartan—Chest pain—Methotrexate—testicular cancer	0.000109	0.000597	CcSEcCtD
Irbesartan—Myalgia—Methotrexate—testicular cancer	0.000109	0.000597	CcSEcCtD
Irbesartan—Tension—Doxorubicin—testicular cancer	0.000109	0.000596	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—testicular cancer	0.000109	0.000595	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000108	0.000593	CcSEcCtD
Irbesartan—Malaise—Epirubicin—testicular cancer	0.000108	0.000592	CcSEcCtD
Irbesartan—Discomfort—Methotrexate—testicular cancer	0.000108	0.00059	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—testicular cancer	0.000108	0.00059	CcSEcCtD
Irbesartan—Vertigo—Epirubicin—testicular cancer	0.000108	0.00059	CcSEcCtD
Irbesartan—Syncope—Epirubicin—testicular cancer	0.000108	0.000589	CcSEcCtD
Irbesartan—Leukopenia—Epirubicin—testicular cancer	0.000107	0.000588	CcSEcCtD
Irbesartan—Muscle spasms—Doxorubicin—testicular cancer	0.000107	0.000584	CcSEcCtD
Irbesartan—Loss of consciousness—Epirubicin—testicular cancer	0.000105	0.000577	CcSEcCtD
Irbesartan—Cough—Epirubicin—testicular cancer	0.000105	0.000573	CcSEcCtD
Irbesartan—Anaphylactic shock—Methotrexate—testicular cancer	0.000105	0.000572	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—testicular cancer	0.000105	0.000572	CcSEcCtD
Irbesartan—Infection—Methotrexate—testicular cancer	0.000104	0.000569	CcSEcCtD
Irbesartan—Nausea—Etoposide—testicular cancer	0.000104	0.000568	CcSEcCtD
Irbesartan—Hypertension—Epirubicin—testicular cancer	0.000104	0.000567	CcSEcCtD
Irbesartan—Ill-defined disorder—Doxorubicin—testicular cancer	0.000103	0.000564	CcSEcCtD
Irbesartan—Nervous system disorder—Methotrexate—testicular cancer	0.000103	0.000561	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—testicular cancer	0.000103	0.000561	CcSEcCtD
Irbesartan—Thrombocytopenia—Methotrexate—testicular cancer	0.000102	0.00056	CcSEcCtD
Irbesartan—Myalgia—Epirubicin—testicular cancer	0.000102	0.000559	CcSEcCtD
Irbesartan—Arthralgia—Epirubicin—testicular cancer	0.000102	0.000559	CcSEcCtD
Irbesartan—Chest pain—Epirubicin—testicular cancer	0.000102	0.000559	CcSEcCtD
Irbesartan—Agitation—Doxorubicin—testicular cancer	0.000102	0.000558	CcSEcCtD
Irbesartan—Anxiety—Epirubicin—testicular cancer	0.000102	0.000557	CcSEcCtD
Irbesartan—Skin disorder—Methotrexate—testicular cancer	0.000102	0.000556	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000101	0.000555	CcSEcCtD
Irbesartan—Hyperhidrosis—Methotrexate—testicular cancer	0.000101	0.000553	CcSEcCtD
Irbesartan—Discomfort—Epirubicin—testicular cancer	0.000101	0.000552	CcSEcCtD
Irbesartan—Malaise—Doxorubicin—testicular cancer	0.0001	0.000548	CcSEcCtD
Irbesartan—Dry mouth—Epirubicin—testicular cancer	9.99e-05	0.000547	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—testicular cancer	9.97e-05	0.000546	CcSEcCtD
Irbesartan—Anorexia—Methotrexate—testicular cancer	9.97e-05	0.000546	CcSEcCtD
Irbesartan—Syncope—Doxorubicin—testicular cancer	9.95e-05	0.000545	CcSEcCtD
Irbesartan—Leukopenia—Doxorubicin—testicular cancer	9.93e-05	0.000544	CcSEcCtD
Irbesartan—Anaphylactic shock—Epirubicin—testicular cancer	9.79e-05	0.000536	CcSEcCtD
Irbesartan—Oedema—Epirubicin—testicular cancer	9.79e-05	0.000536	CcSEcCtD
Irbesartan—Hypotension—Methotrexate—testicular cancer	9.77e-05	0.000535	CcSEcCtD
Irbesartan—Loss of consciousness—Doxorubicin—testicular cancer	9.75e-05	0.000534	CcSEcCtD
Irbesartan—Infection—Epirubicin—testicular cancer	9.73e-05	0.000532	CcSEcCtD
Irbesartan—Cough—Doxorubicin—testicular cancer	9.68e-05	0.00053	CcSEcCtD
Irbesartan—Shock—Epirubicin—testicular cancer	9.63e-05	0.000527	CcSEcCtD
Irbesartan—Nervous system disorder—Epirubicin—testicular cancer	9.6e-05	0.000525	CcSEcCtD
Irbesartan—Thrombocytopenia—Epirubicin—testicular cancer	9.58e-05	0.000525	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—testicular cancer	9.58e-05	0.000524	CcSEcCtD
Irbesartan—Tachycardia—Epirubicin—testicular cancer	9.55e-05	0.000523	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Methotrexate—testicular cancer	9.53e-05	0.000522	CcSEcCtD
Irbesartan—Skin disorder—Epirubicin—testicular cancer	9.51e-05	0.00052	CcSEcCtD
Irbesartan—Hyperhidrosis—Epirubicin—testicular cancer	9.46e-05	0.000518	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—testicular cancer	9.45e-05	0.000517	CcSEcCtD
Irbesartan—Chest pain—Doxorubicin—testicular cancer	9.45e-05	0.000517	CcSEcCtD
Irbesartan—Myalgia—Doxorubicin—testicular cancer	9.45e-05	0.000517	CcSEcCtD
Irbesartan—Anxiety—Doxorubicin—testicular cancer	9.42e-05	0.000515	CcSEcCtD
Irbesartan—Paraesthesia—Methotrexate—testicular cancer	9.39e-05	0.000514	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	9.38e-05	0.000513	CcSEcCtD
Irbesartan—Discomfort—Doxorubicin—testicular cancer	9.34e-05	0.000511	CcSEcCtD
Irbesartan—Anorexia—Epirubicin—testicular cancer	9.33e-05	0.000511	CcSEcCtD
Irbesartan—Dyspnoea—Methotrexate—testicular cancer	9.33e-05	0.00051	CcSEcCtD
Irbesartan—Somnolence—Methotrexate—testicular cancer	9.3e-05	0.000509	CcSEcCtD
Irbesartan—Dry mouth—Doxorubicin—testicular cancer	9.24e-05	0.000506	CcSEcCtD
Irbesartan—Dyspepsia—Methotrexate—testicular cancer	9.21e-05	0.000504	CcSEcCtD
Irbesartan—Hypotension—Epirubicin—testicular cancer	9.15e-05	0.000501	CcSEcCtD
Irbesartan—Decreased appetite—Methotrexate—testicular cancer	9.09e-05	0.000498	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—testicular cancer	9.06e-05	0.000496	CcSEcCtD
Irbesartan—Anaphylactic shock—Doxorubicin—testicular cancer	9.06e-05	0.000496	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Methotrexate—testicular cancer	9.03e-05	0.000494	CcSEcCtD
Irbesartan—Fatigue—Methotrexate—testicular cancer	9.02e-05	0.000494	CcSEcCtD
Irbesartan—Infection—Doxorubicin—testicular cancer	9e-05	0.000492	CcSEcCtD
Irbesartan—Pain—Methotrexate—testicular cancer	8.95e-05	0.00049	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Epirubicin—testicular cancer	8.92e-05	0.000488	CcSEcCtD
Irbesartan—Shock—Doxorubicin—testicular cancer	8.91e-05	0.000488	CcSEcCtD
Irbesartan—Nervous system disorder—Doxorubicin—testicular cancer	8.88e-05	0.000486	CcSEcCtD
Irbesartan—Thrombocytopenia—Doxorubicin—testicular cancer	8.87e-05	0.000485	CcSEcCtD
Irbesartan—Tachycardia—Doxorubicin—testicular cancer	8.84e-05	0.000484	CcSEcCtD
Irbesartan—Skin disorder—Doxorubicin—testicular cancer	8.8e-05	0.000481	CcSEcCtD
Irbesartan—Paraesthesia—Epirubicin—testicular cancer	8.79e-05	0.000481	CcSEcCtD
Irbesartan—Hyperhidrosis—Doxorubicin—testicular cancer	8.76e-05	0.000479	CcSEcCtD
Irbesartan—Dyspnoea—Epirubicin—testicular cancer	8.73e-05	0.000478	CcSEcCtD
Irbesartan—Somnolence—Epirubicin—testicular cancer	8.7e-05	0.000476	CcSEcCtD
Irbesartan—Anorexia—Doxorubicin—testicular cancer	8.63e-05	0.000472	CcSEcCtD
Irbesartan—AGTR1—Peptide ligand-binding receptors—INSL3—testicular cancer	8.62e-05	0.0407	CbGpPWpGaD
Irbesartan—Feeling abnormal—Methotrexate—testicular cancer	8.62e-05	0.000472	CcSEcCtD
Irbesartan—Dyspepsia—Epirubicin—testicular cancer	8.62e-05	0.000472	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methotrexate—testicular cancer	8.55e-05	0.000468	CcSEcCtD
Irbesartan—Decreased appetite—Epirubicin—testicular cancer	8.51e-05	0.000466	CcSEcCtD
Irbesartan—Hypotension—Doxorubicin—testicular cancer	8.46e-05	0.000463	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Epirubicin—testicular cancer	8.45e-05	0.000462	CcSEcCtD
Irbesartan—Fatigue—Epirubicin—testicular cancer	8.44e-05	0.000462	CcSEcCtD
Irbesartan—Constipation—Epirubicin—testicular cancer	8.37e-05	0.000458	CcSEcCtD
Irbesartan—Pain—Epirubicin—testicular cancer	8.37e-05	0.000458	CcSEcCtD
Irbesartan—Urticaria—Methotrexate—testicular cancer	8.31e-05	0.000455	CcSEcCtD
Irbesartan—Abdominal pain—Methotrexate—testicular cancer	8.27e-05	0.000453	CcSEcCtD
Irbesartan—Body temperature increased—Methotrexate—testicular cancer	8.27e-05	0.000453	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—testicular cancer	8.25e-05	0.000452	CcSEcCtD
Irbesartan—Paraesthesia—Doxorubicin—testicular cancer	8.13e-05	0.000445	CcSEcCtD
Irbesartan—Dyspnoea—Doxorubicin—testicular cancer	8.08e-05	0.000442	CcSEcCtD
Irbesartan—Feeling abnormal—Epirubicin—testicular cancer	8.07e-05	0.000441	CcSEcCtD
Irbesartan—Somnolence—Doxorubicin—testicular cancer	8.05e-05	0.000441	CcSEcCtD
Irbesartan—Gastrointestinal pain—Epirubicin—testicular cancer	8.01e-05	0.000438	CcSEcCtD
Irbesartan—Dyspepsia—Doxorubicin—testicular cancer	7.97e-05	0.000436	CcSEcCtD
Irbesartan—Decreased appetite—Doxorubicin—testicular cancer	7.87e-05	0.000431	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Doxorubicin—testicular cancer	7.82e-05	0.000428	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—testicular cancer	7.81e-05	0.000427	CcSEcCtD
Irbesartan—Urticaria—Epirubicin—testicular cancer	7.78e-05	0.000426	CcSEcCtD
Irbesartan—Pain—Doxorubicin—testicular cancer	7.75e-05	0.000424	CcSEcCtD
Irbesartan—Constipation—Doxorubicin—testicular cancer	7.75e-05	0.000424	CcSEcCtD
Irbesartan—Body temperature increased—Epirubicin—testicular cancer	7.74e-05	0.000423	CcSEcCtD
Irbesartan—Abdominal pain—Epirubicin—testicular cancer	7.74e-05	0.000423	CcSEcCtD
Irbesartan—Hypersensitivity—Methotrexate—testicular cancer	7.71e-05	0.000422	CcSEcCtD
Irbesartan—Asthenia—Methotrexate—testicular cancer	7.51e-05	0.000411	CcSEcCtD
Irbesartan—Feeling abnormal—Doxorubicin—testicular cancer	7.46e-05	0.000408	CcSEcCtD
Irbesartan—Gastrointestinal pain—Doxorubicin—testicular cancer	7.41e-05	0.000405	CcSEcCtD
Irbesartan—Pruritus—Methotrexate—testicular cancer	7.4e-05	0.000405	CcSEcCtD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	7.37e-05	0.0348	CbGpPWpGaD
Irbesartan—JUN—BCR signaling pathway—BCL10—testicular cancer	7.24e-05	0.0342	CbGpPWpGaD
Irbesartan—Hypersensitivity—Epirubicin—testicular cancer	7.21e-05	0.000395	CcSEcCtD
Irbesartan—Urticaria—Doxorubicin—testicular cancer	7.2e-05	0.000394	CcSEcCtD
Irbesartan—Abdominal pain—Doxorubicin—testicular cancer	7.16e-05	0.000392	CcSEcCtD
Irbesartan—Body temperature increased—Doxorubicin—testicular cancer	7.16e-05	0.000392	CcSEcCtD
Irbesartan—Diarrhoea—Methotrexate—testicular cancer	7.16e-05	0.000392	CcSEcCtD
Irbesartan—Asthenia—Epirubicin—testicular cancer	7.02e-05	0.000384	CcSEcCtD
Irbesartan—Pruritus—Epirubicin—testicular cancer	6.93e-05	0.000379	CcSEcCtD
Irbesartan—Dizziness—Methotrexate—testicular cancer	6.92e-05	0.000379	CcSEcCtD
Irbesartan—Diarrhoea—Epirubicin—testicular cancer	6.7e-05	0.000367	CcSEcCtD
Irbesartan—Hypersensitivity—Doxorubicin—testicular cancer	6.67e-05	0.000365	CcSEcCtD
Irbesartan—Vomiting—Methotrexate—testicular cancer	6.65e-05	0.000364	CcSEcCtD
Irbesartan—Rash—Methotrexate—testicular cancer	6.6e-05	0.000361	CcSEcCtD
Irbesartan—Dermatitis—Methotrexate—testicular cancer	6.59e-05	0.000361	CcSEcCtD
Irbesartan—Headache—Methotrexate—testicular cancer	6.55e-05	0.000359	CcSEcCtD
Irbesartan—Asthenia—Doxorubicin—testicular cancer	6.5e-05	0.000356	CcSEcCtD
Irbesartan—UGT1A3—Phase II conjugation—HPGDS—testicular cancer	6.47e-05	0.0305	CbGpPWpGaD
Irbesartan—Dizziness—Epirubicin—testicular cancer	6.47e-05	0.000354	CcSEcCtD
Irbesartan—Pruritus—Doxorubicin—testicular cancer	6.41e-05	0.000351	CcSEcCtD
Irbesartan—Vomiting—Epirubicin—testicular cancer	6.22e-05	0.000341	CcSEcCtD
Irbesartan—Nausea—Methotrexate—testicular cancer	6.21e-05	0.00034	CcSEcCtD
Irbesartan—Diarrhoea—Doxorubicin—testicular cancer	6.2e-05	0.000339	CcSEcCtD
Irbesartan—Rash—Epirubicin—testicular cancer	6.17e-05	0.000338	CcSEcCtD
Irbesartan—Dermatitis—Epirubicin—testicular cancer	6.17e-05	0.000337	CcSEcCtD
Irbesartan—Headache—Epirubicin—testicular cancer	6.13e-05	0.000336	CcSEcCtD
Irbesartan—Dizziness—Doxorubicin—testicular cancer	5.99e-05	0.000328	CcSEcCtD
Irbesartan—Nausea—Epirubicin—testicular cancer	5.81e-05	0.000318	CcSEcCtD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	5.78e-05	0.0273	CbGpPWpGaD
Irbesartan—Vomiting—Doxorubicin—testicular cancer	5.76e-05	0.000315	CcSEcCtD
Irbesartan—PTGS1—Arachidonic acid metabolism—HPGDS—testicular cancer	5.73e-05	0.027	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—BCL10—testicular cancer	5.72e-05	0.027	CbGpPWpGaD
Irbesartan—Rash—Doxorubicin—testicular cancer	5.71e-05	0.000313	CcSEcCtD
Irbesartan—Dermatitis—Doxorubicin—testicular cancer	5.71e-05	0.000312	CcSEcCtD
Irbesartan—Headache—Doxorubicin—testicular cancer	5.67e-05	0.000311	CcSEcCtD
Irbesartan—EDNRA—GPCR ligand binding—INSL3—testicular cancer	5.61e-05	0.0265	CbGpPWpGaD
Irbesartan—JUN—B Cell Receptor Signaling Pathway—BCL10—testicular cancer	5.39e-05	0.0254	CbGpPWpGaD
Irbesartan—Nausea—Doxorubicin—testicular cancer	5.38e-05	0.000294	CcSEcCtD
Irbesartan—JUN—Osteopontin-mediated events—MMP2—testicular cancer	4.89e-05	0.0231	CbGpPWpGaD
Irbesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—testicular cancer	4.47e-05	0.0211	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—INSL3—testicular cancer	4.41e-05	0.0208	CbGpPWpGaD
Irbesartan—JUN—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—testicular cancer	4.25e-05	0.02	CbGpPWpGaD
Irbesartan—JUN—FGF signaling pathway—FGFR3—testicular cancer	3.86e-05	0.0182	CbGpPWpGaD
Irbesartan—UGT1A3—Biological oxidations—HPGDS—testicular cancer	3.79e-05	0.0179	CbGpPWpGaD
Irbesartan—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	3.7e-05	0.0175	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	3.33e-05	0.0157	CbGpPWpGaD
Irbesartan—JUN—Senescence-Associated Secretory Phenotype (SASP)—H2AFZ—testicular cancer	3.31e-05	0.0156	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—INSL3—testicular cancer	3.17e-05	0.015	CbGpPWpGaD
Irbesartan—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	3.01e-05	0.0142	CbGpPWpGaD
Irbesartan—JUN—Oxidative Stress Induced Senescence—H2AFZ—testicular cancer	3e-05	0.0141	CbGpPWpGaD
Irbesartan—JUN—ATF-2 transcription factor network—MMP2—testicular cancer	2.92e-05	0.0138	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—INSL3—testicular cancer	2.88e-05	0.0136	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	2.81e-05	0.0133	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	2.75e-05	0.013	CbGpPWpGaD
Irbesartan—JUN—LPA receptor mediated events—MMP2—testicular cancer	2.74e-05	0.0129	CbGpPWpGaD
Irbesartan—JUN—AGE/RAGE pathway—MMP2—testicular cancer	2.67e-05	0.0126	CbGpPWpGaD
Irbesartan—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	2.58e-05	0.0122	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—INSL3—testicular cancer	2.49e-05	0.0117	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—STK11—testicular cancer	2.46e-05	0.0116	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—testicular cancer	2.29e-05	0.0108	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—INSL3—testicular cancer	2.26e-05	0.0107	CbGpPWpGaD
Irbesartan—PTGS1—Biological oxidations—HPGDS—testicular cancer	2.13e-05	0.0101	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—H2AFZ—testicular cancer	2.1e-05	0.0099	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	2.04e-05	0.00964	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	2.01e-05	0.00947	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—INSL3—testicular cancer	1.7e-05	0.00803	CbGpPWpGaD
Irbesartan—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	1.64e-05	0.00773	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—H2AFZ—testicular cancer	1.59e-05	0.00748	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	1.49e-05	0.00704	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—MMP2—testicular cancer	1.46e-05	0.00691	CbGpPWpGaD
Irbesartan—CYP2C8—Biological oxidations—HPGDS—testicular cancer	1.38e-05	0.0065	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	1.37e-05	0.00647	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—INSL3—testicular cancer	1.34e-05	0.0063	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—BCL10—testicular cancer	1.29e-05	0.00611	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—HPGDS—testicular cancer	1.13e-05	0.00534	CbGpPWpGaD
Irbesartan—CYP2C9—Biological oxidations—HPGDS—testicular cancer	1.12e-05	0.00529	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—INSL3—testicular cancer	9.98e-06	0.00471	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—HPGDS—testicular cancer	9.58e-06	0.00452	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	8.19e-06	0.00387	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KITLG—testicular cancer	7.8e-06	0.00368	CbGpPWpGaD
Irbesartan—JUN—Immune System—BCL10—testicular cancer	7.54e-06	0.00356	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—HPGDS—testicular cancer	7.4e-06	0.00349	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—HPGDS—testicular cancer	6.48e-06	0.00306	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—FGFR3—testicular cancer	5.8e-06	0.00274	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—H2AFZ—testicular cancer	5.45e-06	0.00257	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—STK11—testicular cancer	5.42e-06	0.00256	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KIT—testicular cancer	5.32e-06	0.00251	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	5.29e-06	0.0025	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KITLG—testicular cancer	5.01e-06	0.00236	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—STK11—testicular cancer	4.71e-06	0.00222	CbGpPWpGaD
Irbesartan—JUN—Immune System—KITLG—testicular cancer	4.54e-06	0.00214	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.31e-06	0.00203	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—H2AFZ—testicular cancer	4.27e-06	0.00202	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STK11—testicular cancer	4.25e-06	0.00201	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KITLG—testicular cancer	3.93e-06	0.00186	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—FGFR3—testicular cancer	3.72e-06	0.00176	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.68e-06	0.00174	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—HPGDS—testicular cancer	3.65e-06	0.00172	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KIT—testicular cancer	3.42e-06	0.00161	CbGpPWpGaD
Irbesartan—JUN—Immune System—FGFR3—testicular cancer	3.38e-06	0.00159	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—H2AFZ—testicular cancer	3.19e-06	0.00151	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STK11—testicular cancer	3.18e-06	0.0015	CbGpPWpGaD
Irbesartan—JUN—Immune System—KIT—testicular cancer	3.1e-06	0.00146	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KITLG—testicular cancer	2.94e-06	0.00139	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—FGFR3—testicular cancer	2.92e-06	0.00138	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KIT—testicular cancer	2.68e-06	0.00127	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—STK11—testicular cancer	2.65e-06	0.00125	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HPGDS—testicular cancer	2.36e-06	0.00111	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FGFR3—testicular cancer	2.18e-06	0.00103	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KIT—testicular cancer	2e-06	0.000946	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HPGDS—testicular cancer	1.93e-06	0.000913	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HPGDS—testicular cancer	1.92e-06	0.000905	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—STK11—testicular cancer	1.71e-06	0.000808	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HPGDS—testicular cancer	1.64e-06	0.000773	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—STK11—testicular cancer	1.41e-06	0.000663	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—STK11—testicular cancer	1.39e-06	0.000658	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HPGDS—testicular cancer	1.26e-06	0.000597	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—STK11—testicular cancer	1.19e-06	0.000562	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—STK11—testicular cancer	9.19e-07	0.000434	CbGpPWpGaD
